Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The high failure rate in drug development is analogous to trying to repair a car with no mechanical knowledge—it's just "banging on different parts." This highlights the industry's need to shift from observing correlations to understanding the fundamental biological mechanisms of disease.

The catastrophic failure rate in drug development isn't just bad luck; it's a structural problem. It originates from the very first decision: researchers, biased by existing literature and simplistic models, fixate on a single biochemical target, ignoring the body's complex, multi-faceted nature.

Despite their potential to save time and money, a large majority of commercial Phase 2 and 3 clinical trials in 2023 did not include a pre-planned interim analysis. This indicates a massive, underutilized opportunity to identify failing drugs sooner and reallocate resources more effectively.

The process of testing drugs in humans—clinical development—is a massive, under-studied bottleneck, accounting for 70% of drug development costs. Despite its importance, there is surprisingly little public knowledge, academic research, or even basic documentation on how to improve this crucial stage.

Despite massive unmet need, drug development in higher-risk MDS has stalled because many drugs promising in Phase 1/2 trials fail in Phase 3. Their toxicities, manageable in smaller trials, become prohibitive for the older, co-morbid patient population in larger studies, making a favorable safety profile a critical prerequisite for success.

Scientists often design trials to answer every possible academic question, which adds complexity and patient burden. Drug development trials should be ruthlessly focused on two things only: safety and efficacy. All other extraneous research can wait for post-approval studies.

While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.

The standard pharmaceutical industry model is to abandon a drug if it fails in trials. A leading scientist argues this is a major flaw. Academic centers can provide the 'proper science' to analyze *why* a drug failed, potentially rescuing valuable compounds or informing future drug design.